Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)

Inclusion Criteria: * Requires treatment with IV antibiotic therapy for HABP or VABP * Fulfills clinical and radiographic criteria within 48 hours prior to randomization, with onset of criteria occurring after more than 2 days of hospitalization or within 7 days after discharge from a hospital for HABP; or at least 2 days after mechanical ventilation (for VABP) * Has an adequate baseline (at or within 2 days of screening) lower respiratory tract specimen obtained for Gram stain and culture * Has an infection known or thought to be, in the opinion of the investigator, caused by microorganisms susceptible to the IV study therapy * Agrees to allow any bacterial isolates obtained from protocol-required specimens related to the current infection to be provided to the Central Microbiology Reference Laboratory for study-related microbiological testing and long-term storage * Males agree to use contraception as detailed in protocol from the time of providing informed consent through completion of the study and refrain from donating sperm during this period * Females are not pregnant, not breastfeeding, and are either: a.) Not a woman of childbearing potential (WOCBP) OR b.) A WOCBP who agrees to follow the contraceptive guidance from the time of providing informed consent through completion of the study * If a penicillin skin test is required by local clinical practice, the participant must have a negative skin test result for allergy to penicillin Exclusion Criteria: * Has a base…